Option chain shows key data for Redsense Medical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Redsense Medical.

Redsense Medical (OTC:RDSNF) Stock, Option Chain

Redsense Medical AB manufactures and sells blood loss detection devices in Sweden. The company has developed a monitoring system that can detect the first sign of a blood leak using patented fiber optic technology. The products of the company include Alarm Unit, Venous Needle Patch, Sensor Patch, and others.

Redsense Medical AB

Current CEO Lou Haddad will retire at the end of 2024 but will retain the role of Executive Chairman of the Company's Board of Directors. Additionally, the Board of Directors expects to appoint Tibbetts to the Board of Directors upon his elevation to Chief Executive Officer.

News

Management

Armada Hoffler Names Shawn Tibbetts As CEO, Effective January 1, 2025; Current CEO Lou Haddad To Retain The Role Of Executive Chairman

-The New York Stock Exchange ("NYSE", the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Spirit Airlines, Inc. (the "Company") — ticker symbol SAVE — from the NYSE. Trading in the Company's common stock will be suspended immediately.
NYSE Regulation reached its decision that the Company is no longer suitable for listing pursuant to NYSE Listed Company Manual Section 802.01D after the Company's November 18, 2024 press release and Form 8-K disclosures that the Company has commenced a prearranged chapter 11 process in the United States Bankruptcy Court for the Southern District of New York. In reaching its delisting determination, NYSE Regulation notes the Company disclosed that all of the Company's existing common stock and other equity interests will be cancelled without any distributions to the holders of such common stock and other equity interests on account thereof.
The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

SAVE

NYSE To Commence Delisting Proceedings Against Spirit Airlines, Effective Immediately

Guidance

Healthpeak Properties Raises FY24 AFFO From $1.56-$1.58 To $1.57-$1.59

MCHP

Microchip Technology Announces Ganesh Moorthy Is Retiring As CEO, President And Board Member; Steve Sanghi Appointed Interim CEO

Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced that it has commenced an underwritten public offering of up to $200.0 million of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $30.0 million of shares of common stock at the public offering price, less the underwriting discount. All of the shares of common stock and pre-funded warrants in the offering will be sold by Spyre.&nbsp;
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC, Goldman Sachs &amp; Co. LLC, Evercore Group L.L.C., and Guggenheim Securities, LLC are acting as the joint book-running managers for the proposed offering. LifeSci Capital LLC is acting as lead manager for the proposed offering.

Offerings

SYRE

Spyre Therapeutics Announces Proposed $200M Public Offering Of Its Common Stock And Pre-Funded Warrants

WIIM

OMCL

Omnicell shares are trading lower after the company announced a proposed private placement of $150 million in convertible senior notes.

Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) ("Omnicell") today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Omnicell also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes.
The notes will be general unsecured, senior obligations of Omnicell, will accrue interest payable semiannually in arrears and will mature on December 1, 2029, unless earlier converted, redeemed or repurchased. Upon conversion, Omnicell will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Omnicell's common stock or a combination of cash and shares of Omnicell's common stock, at Omnicell's election, in respect of the remainder, if any, of Omnicell's conversion obligation in excess of the aggregate principal amount of the notes being converted. The interest rate, initial conversion rate, redemption or repurchase rights and other terms of the notes will be determined at the time of pricing of the offering.

Omnicell Announces Proposed Private Placement Of $150M Of Convertible Senior Notes Due 2029

Donald Trump was viewed as the more pro-cryptocurrency presidential candidate in the 2024 election and his support for crypto could get another push with a report that his media company is acquiring a<a href="https://www.benzinga.com/markets/cryptocurrency/21/01/19071375/spac-surges-64-on-report-of-merger-talks-with-ice-owned-crypto-exchange-bakkt"> cryptocurrency trading company.</a>
What Happened: Shares of Bakkt Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NASDAQ">BKKT</a>) are soaring Monday on reports the cryptocurrency company, <a href="https://www.benzinga.com/markets/cryptocurrency/21/04/20550003/3-cryptocurrency-spacs-that-could-run-on-a-successful-coinbase-ipo">which went public </a>in October 2021 via SPAC merger, is being acquired by Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>).
The media company co-founded by Trump, which owns the Truth Social platform, is in advanced talks to acquire Bakkt, <a href="https://www.ft.com/content/d7f921d5-3668-4b6b-a98d-2681ad73610f">according </a>to the Financial Times. The report said Trump Media &amp; Technology Group would acquire the cryptocurrency company, which is backed by Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), in an all-share deal.
Benzinga reached out to Trump Media &amp; Technology Group for comment on the report and will update the story accordingly. Benzinga has also contacted Bakkt for comment. 
Bakkt's first CEO was Kelly Loeffler, who was previously a member of the U.S. Senate, representing the state of Georgia as a Republican. Loeffler is helping to organize Trump's inauguration in January and has close ties to the president-elect.
The Intercontinental Exchange, which owns the New York Stock Exchange, owns a reported 55% of Bakkt. The exchange company would have to give approval to any such sale to the Trump media company.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Bakkt <a href="https://www.benzinga.com/news/24/06/39234822/bakkt-holdings-explores-potential-sale-or-breakup-amid-crypto-sector-consolidation">said in June</a> it was exploring strategic alternatives that could include a sale or breakup of the company.
The company previously said its crypto custody business could be wound down. This segment might not be included in the buyout, according to the report. Bakkt is planning to build a crypto trading platform geared to institutional investors.
DJT shares have experienced high volatility and an increased valuation after Trump won the 2024 election.
Trump's <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41096120/if-you-invested-1-000-in-bitcoin-when-donald-trump-said-he-wasnt-a-fan-heres-how-much-youd">pro-crypto stance</a> may have helped elevate Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies to all-time highs following his <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">2024 election win.</a>
An acquisition of Bakkt would push Trump's media company and the president-elect deeper into the cryptocurrency sector, which comes after he promoted a crypto venture called World Liberty Financial with business partners.
BKKT, DJT Price Action: Bakkt stock was halted several times after the report and ended Monday&#8217;s session 163.04% higher at $29.71 versus a 52-week trading range of $5.57 to $68.75. Bakkt shares are down 44% year-to-date in 2024.
Trump Media &amp; Technology stock is up 16.65% to $32.78 Monday versus a 52-week trading range of $22.55 to $79.38. Trump Media &amp; Technology stock is up 85% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41760961/djt-stock-volatile-on-election-day-donald-trumps-media-company-reports-q3-earnings-growth-initiativ">DJT Stock Volatile On Election Day: Donald Trump&#8217;s Media Company Reports Q3 Earnings, Growth Initiatives</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Social Media

Politics

Movers

Trading Ideas

$BTC

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Trump Digs Deeper Into Cryptocurrency? Bakkt Shares Soar On Reported Interest From President-Elect's Media Company

The consolidation of the Company's welded wire manufacturing operations is expected to result in the elimination of up to 35 positions at the Warren facility. It is anticipated that operations at the Warren facility will cease by the end of November 2024. Insteel expects to incur a restructuring charge of approximately $1.9 million related to the facility's closure.

IIIN

Insteel Industries Plans Closing Its Facility In Warren, Ohio; Resulting In Elimination Of Up To 35 Positions; Expects To Incur Restructuring Charge Of $1.9M

Fiscal 2025 Financial Guidance
<ul>
<li>AECOM expects to deliver record net service revenue and profitability, margins and continued strong cash flow conversion, including:
<ul>
<li>Organic NSR2 growth of 5% to 8%.
<ul>
<li>Expect phasing to follow a normal seasonal pattern with accelerating growth as the year progresses.</li>
</ul>
</li>
<li>Adjusted1 EBITDA4 of between $1,170 million and $1,210 million, reflecting an increase of 9% at the mid-point over fiscal 2024.</li>
<li>An adjusted EBITDA margin5 of 16.3%, representing a 30 basis point increase from fiscal 2024.</li>
<li>Adjusted1 EPS of between $5.00 and $5.20, reflecting an increase of 13% at the mid-point compared to fiscal 2024.</li>
<li>100%+ free cash flow6 conversion.</li>
</ul>
</li>
<li>Other assumptions incorporated into guidance:
<ul>
<li>An average fully diluted share count of 134 million, which reflects only shares repurchased to-date, though the Company intends to continue repurchasing stock that would provide a benefit to per share earnings.</li>
<li>An adjusted effective tax rate of approximately 24% for the full year.
<ul>
<li>The Company expects to maintain an approximately 24% tax rate for the next several years.</li>
</ul>
</li>
</ul>
</li>
<li>See the Regulation G Information tables at the end of this release for a reconciliation of non-GAAP measures to the most directly comparable GAAP measures.</li>
</ul>
Long-Term Financial Framework for Value Creation
<ul>
<li>The Company's long-term financial framework includes expectations to deliver annually:
<ul>
<li>Organic NSR2 growth of 5% to 8%.</li>
<li>At least 20 to 30 basis points of adjusted EBITDA margin5 expansion.</li>
<li>At least 100% conversion of adjusted net income to free cash flow6.</li>
<li>Double-digit adjusted EPS1 and free cash flow6 per share growth.</li>
</ul>
</li>
<li>The Company also expects to achieve an at least 17% adjusted EBITDA margin5 exiting fiscal year 2025 and an at least 25% ROIC9 over the long term.</li>
</ul>

AECOM Long-term Financial Framework Includes Expectations To Deliver Annually: Organic NSR Growth Of 5%-8%; At Least 20 To 30 Basis Points Of Adjusted EBITDA Margin Expansion; At Least 100% Conversion Of Adjusted Net Income To Free Cash Flow; Double-Digit Adjusted EPS And Free Cash Flow Per Share Growth; Expects To Achieve An At Least 17% Adjusted EBITDA Margin Exiting Fiscal Year 2025 And An At Least 25% ROIC Over The Long Term

NWTN

NWTN Receives Delisting Determination Notice From Nasdaq

NRXP

NRx Pharmaceuticals Appoints Michael Abrams As CFO

General

CDRO

Codere Online Receives Delisting Notice From Nasdaq Due To Public Reports Rule; Co. Submits Appeal

Buybacks

AECOM Increases Share Repurchase Authorization To $1B

Dividends

AECOM Increases Quarterly Dividend From $0.22 To $0.26

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="4" rowspan="1">FY2025 GAAP EPS Guidance based on Adjusted EPS Guidance</td>
</tr>
<tr>
<td colspan="2" rowspan="1">(all figures approximate)</td>
<td colspan="1" rowspan="1">Fiscal Year End 2025</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP EPS guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$4.96 to $5.16</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS excludes:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of intangible assets</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.01</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of deferred financing fees</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.04</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax effect of the above items</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($0.01)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$5.00 to $5.20</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">FY2025 GAAP Net Income from Continuing Operations Guidance based on Adjusted EBITDA Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(in millions, all figures approximate)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Fiscal Year End 2025</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP net income from continuing operations guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$724 to $743</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income attributable to noncontrolling interest from continuing operations</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($60) to ($50)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income attributable to AECOM from continuing operations</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$664 to $693</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted net income attributable to AECOM from continuing operations excludes:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of intangible assets</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of deferred financing fees</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$5</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax effect of the above items</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($1) to ($2)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted net income attributable to AECOM from continuing operations</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$670 to $698</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA excludes:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$160</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted interest expense, net</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$129</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax expense, including tax effect of above items</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$211 to $223</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,170 to $1,210</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Note: Variances in tables are due to rounding.</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

AECOM Sees FY25 EPS $5.00-$5.20 Vs $5.02 Est.

Tuya (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TUYA#NYSE">TUYA</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.03 by 33.33 percent. The company reported quarterly sales of $81.60 million which beat the analyst consensus estimate of $75.49 million by 8.09 percent. This is a 33.57 percent increase over sales of $61.09 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

TUYA

Tuya Q3 2024 Adj EPS $0.02 Misses $0.03 Estimate, Sales $81.60M Beat $75.49M Estimate

GOVX

GeoVax Labs Received Notice From Nasdaq Notifying The Company That, Co. Complies With Stockholders' Equity Listing Rule

– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need –
– Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting –
– Positive opinion on E.U. orphan drug designation follows U.S. FDA fast track designation, highlighting growing recognition of the potential of tobevibart and elebsiran in chronic hepatitis delta –

Biotech

EMA Issued Opinion For Vir Biotechnology's Application For Orphan Drug Designation For Tobevibart And Elebsiran In Chronic Hepatitis Delta

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.24 by 2.42 percent. This is a 25.74 percent increase over earnings of $1.01 per share from the same period last year. The company reported quarterly sales of $4.11 billion which missed the analyst consensus estimate of $4.14 billion by 0.64 percent. This is a 106.89K percent increase over sales of $3.84 million the same period last year.

Comments

Redsense Medical

Redsense Medical (RDSNF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga